Literature DB >> 32697031

Outcomes of brief and enhanced cognitive-behavioural therapy for adults with non-underweight eating disorders: A non-randomized comparison.

Madeleine Tatham1, Chloe Hewitt1, Glenn Waller2.   

Abstract

OBJECTIVE: Cognitive-behavioural therapy (CBT) is an efficacious and effective treatment for eating disorders, and is particularly valuable in the treatment of non-underweight cases (e.g., bulimia nervosa; binge eating-disorders). However, its recommended length for such cases (up to 20 sessions) makes it a relatively costly therapy. It has been suggested that a 10-session version (CBT-T) can also be effective, but there has been no direct comparison between the two forms (10 vs. 20 sessions).
METHOD: This study reports the outcomes of brief and standard-length CBT for non-underweight eating disorders, comparing two cohorts of patients from the same clinic (N = 55 and 138, respectively).
RESULTS: The two therapies had very similar results in terms of eating pathology, remission rate, and improved quality of life. Each showed substantial change by the mid-point of therapy and up to 6-month follow-up.
CONCLUSION: It appears that brief CBT (CBT-T) is as effective as existing 20-session CBT, and is less demanding of time and resource. The findings need to be replicated in a randomized control trial before this conclusion can be made definitive.
© 2020 The Authors. European Eating Disorders Review published by Eating Disorders Association and John Wiley & Sons Ltd.

Entities:  

Keywords:  cognitive-behavioural therapy; eating disorders; outcomes; quality of life

Mesh:

Year:  2020        PMID: 32697031     DOI: 10.1002/erv.2765

Source DB:  PubMed          Journal:  Eur Eat Disord Rev        ISSN: 1072-4133


  1 in total

1.  A feasibility study of the delivery of online brief cognitive-behavioral therapy (CBT-T) for eating disorder pathology in the workplace.

Authors:  Carla T Toro; Tabitha Jackson; Agatha S Payne; Lukasz Walasek; Sean Russell; Guy Daly; Glenn Waller; Caroline Meyer
Journal:  Int J Eat Disord       Date:  2022-03-15       Impact factor: 5.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.